An international survey of classification and treatment choices for group D retinoblastoma

Christina Scelfo, Jasmine H. Francis, Vikas Khetan, Thomas Jenkins, Brian Marr, David H. Abramson, Carol L. Shields, Jacob Pe’er, Francis Munier, Jesse Berry, J. William Harbour, Andrey Yarovoy, Evandro Lucena, Timothy G. Murray, Pooja Bhagia, Evelyn Paysse, Samuray Tuncer, Guillermo L. Chantada, Annette C. Moll, Tatiana Ushakova & 17 others David A. Plager, Islamov Ziyovuddin, Carlos A. Leal, Miguel A. Materin, Xun Da Ji, Jose W. Cursino, Rodrigo Polania, Hayyam Kiratli, Charlotta All-Ericsson, Rejin Kebudi, Santosh G. Honavar, Vicktoria Vishnevskia-Dai, Sidnel Epelman, Anthony B. Daniels, Jeanie D. Ling, Fousseyni Traore, Marco A. Ramirez-Ortiz

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

• AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. • METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. • RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Childrenfs Hospital of Los Angeles (CHLA) version, 33% used the Childrenfs Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). • CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.

Original languageEnglish
Pages (from-to)961-967
Number of pages7
JournalInternational Journal of Ophthalmology
Volume10
Issue number6
DOIs
Publication statusPublished - 18 Jun 2017

Cite this

Scelfo, C., Francis, J. H., Khetan, V., Jenkins, T., Marr, B., Abramson, D. H., ... Ramirez-Ortiz, M. A. (2017). An international survey of classification and treatment choices for group D retinoblastoma. International Journal of Ophthalmology, 10(6), 961-967. https://doi.org/10.18240/ijo.2017.06.20
Scelfo, Christina ; Francis, Jasmine H. ; Khetan, Vikas ; Jenkins, Thomas ; Marr, Brian ; Abramson, David H. ; Shields, Carol L. ; Pe’er, Jacob ; Munier, Francis ; Berry, Jesse ; Harbour, J. William ; Yarovoy, Andrey ; Lucena, Evandro ; Murray, Timothy G. ; Bhagia, Pooja ; Paysse, Evelyn ; Tuncer, Samuray ; Chantada, Guillermo L. ; Moll, Annette C. ; Ushakova, Tatiana ; Plager, David A. ; Ziyovuddin, Islamov ; Leal, Carlos A. ; Materin, Miguel A. ; Ji, Xun Da ; Cursino, Jose W. ; Polania, Rodrigo ; Kiratli, Hayyam ; All-Ericsson, Charlotta ; Kebudi, Rejin ; Honavar, Santosh G. ; Vishnevskia-Dai, Vicktoria ; Epelman, Sidnel ; Daniels, Anthony B. ; Ling, Jeanie D. ; Traore, Fousseyni ; Ramirez-Ortiz, Marco A. / An international survey of classification and treatment choices for group D retinoblastoma. In: International Journal of Ophthalmology. 2017 ; Vol. 10, No. 6. pp. 961-967.
@article{abbf9e7ed49c45838f93ba26ca6e6f5e,
title = "An international survey of classification and treatment choices for group D retinoblastoma",
abstract = "• AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. • METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. • RESULTS: The survey was completed by 29{\%} of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27{\%} of centers used the Childrenfs Hospital of Los Angeles (CHLA) version, 33{\%} used the Childrenfs Oncology Group (COG) version, 23{\%} used the Philadelphia version, and 17{\%} were unsure. The rate for primary enucleation varied between 0 and 100{\%} and the mean was 29{\%}. By IIRC version, primary enucleation rates were: Philadelphia, 8{\%}; COG, 34{\%}; and CHLA, 37{\%}. By geographic region, primary enucleation rates were: Latin America, 57{\%}; Asia, 40{\%}; Europe, 36{\%}; Africa, 10{\%}, US, 8{\%}; and Middle East, 8{\%}. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57{\%} per center (P<0.0001). • CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.",
keywords = "Cancer, Chemotherapy, Enucleation, Intra-arterial chemotherapy, Oncology, Ophthalmic artery chemosurgery, Retina, Retinoblastoma",
author = "Christina Scelfo and Francis, {Jasmine H.} and Vikas Khetan and Thomas Jenkins and Brian Marr and Abramson, {David H.} and Shields, {Carol L.} and Jacob Pe’er and Francis Munier and Jesse Berry and Harbour, {J. William} and Andrey Yarovoy and Evandro Lucena and Murray, {Timothy G.} and Pooja Bhagia and Evelyn Paysse and Samuray Tuncer and Chantada, {Guillermo L.} and Moll, {Annette C.} and Tatiana Ushakova and Plager, {David A.} and Islamov Ziyovuddin and Leal, {Carlos A.} and Materin, {Miguel A.} and Ji, {Xun Da} and Cursino, {Jose W.} and Rodrigo Polania and Hayyam Kiratli and Charlotta All-Ericsson and Rejin Kebudi and Honavar, {Santosh G.} and Vicktoria Vishnevskia-Dai and Sidnel Epelman and Daniels, {Anthony B.} and Ling, {Jeanie D.} and Fousseyni Traore and Ramirez-Ortiz, {Marco A.}",
year = "2017",
month = "6",
day = "18",
doi = "10.18240/ijo.2017.06.20",
language = "English",
volume = "10",
pages = "961--967",
journal = "International Journal of Ophthalmology",
issn = "2222-3959",
publisher = "Press of International Journal of Ophthalmology",
number = "6",

}

Scelfo, C, Francis, JH, Khetan, V, Jenkins, T, Marr, B, Abramson, DH, Shields, CL, Pe’er, J, Munier, F, Berry, J, Harbour, JW, Yarovoy, A, Lucena, E, Murray, TG, Bhagia, P, Paysse, E, Tuncer, S, Chantada, GL, Moll, AC, Ushakova, T, Plager, DA, Ziyovuddin, I, Leal, CA, Materin, MA, Ji, XD, Cursino, JW, Polania, R, Kiratli, H, All-Ericsson, C, Kebudi, R, Honavar, SG, Vishnevskia-Dai, V, Epelman, S, Daniels, AB, Ling, JD, Traore, F & Ramirez-Ortiz, MA 2017, 'An international survey of classification and treatment choices for group D retinoblastoma' International Journal of Ophthalmology, vol. 10, no. 6, pp. 961-967. https://doi.org/10.18240/ijo.2017.06.20

An international survey of classification and treatment choices for group D retinoblastoma. / Scelfo, Christina; Francis, Jasmine H.; Khetan, Vikas; Jenkins, Thomas; Marr, Brian; Abramson, David H.; Shields, Carol L.; Pe’er, Jacob; Munier, Francis; Berry, Jesse; Harbour, J. William; Yarovoy, Andrey; Lucena, Evandro; Murray, Timothy G.; Bhagia, Pooja; Paysse, Evelyn; Tuncer, Samuray; Chantada, Guillermo L.; Moll, Annette C.; Ushakova, Tatiana; Plager, David A.; Ziyovuddin, Islamov; Leal, Carlos A.; Materin, Miguel A.; Ji, Xun Da; Cursino, Jose W.; Polania, Rodrigo; Kiratli, Hayyam; All-Ericsson, Charlotta; Kebudi, Rejin; Honavar, Santosh G.; Vishnevskia-Dai, Vicktoria; Epelman, Sidnel; Daniels, Anthony B.; Ling, Jeanie D.; Traore, Fousseyni; Ramirez-Ortiz, Marco A.

In: International Journal of Ophthalmology, Vol. 10, No. 6, 18.06.2017, p. 961-967.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - An international survey of classification and treatment choices for group D retinoblastoma

AU - Scelfo, Christina

AU - Francis, Jasmine H.

AU - Khetan, Vikas

AU - Jenkins, Thomas

AU - Marr, Brian

AU - Abramson, David H.

AU - Shields, Carol L.

AU - Pe’er, Jacob

AU - Munier, Francis

AU - Berry, Jesse

AU - Harbour, J. William

AU - Yarovoy, Andrey

AU - Lucena, Evandro

AU - Murray, Timothy G.

AU - Bhagia, Pooja

AU - Paysse, Evelyn

AU - Tuncer, Samuray

AU - Chantada, Guillermo L.

AU - Moll, Annette C.

AU - Ushakova, Tatiana

AU - Plager, David A.

AU - Ziyovuddin, Islamov

AU - Leal, Carlos A.

AU - Materin, Miguel A.

AU - Ji, Xun Da

AU - Cursino, Jose W.

AU - Polania, Rodrigo

AU - Kiratli, Hayyam

AU - All-Ericsson, Charlotta

AU - Kebudi, Rejin

AU - Honavar, Santosh G.

AU - Vishnevskia-Dai, Vicktoria

AU - Epelman, Sidnel

AU - Daniels, Anthony B.

AU - Ling, Jeanie D.

AU - Traore, Fousseyni

AU - Ramirez-Ortiz, Marco A.

PY - 2017/6/18

Y1 - 2017/6/18

N2 - • AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. • METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. • RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Childrenfs Hospital of Los Angeles (CHLA) version, 33% used the Childrenfs Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). • CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.

AB - • AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. • METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. • RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Childrenfs Hospital of Los Angeles (CHLA) version, 33% used the Childrenfs Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). • CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.

KW - Cancer

KW - Chemotherapy

KW - Enucleation

KW - Intra-arterial chemotherapy

KW - Oncology

KW - Ophthalmic artery chemosurgery

KW - Retina

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=85020910381&partnerID=8YFLogxK

U2 - 10.18240/ijo.2017.06.20

DO - 10.18240/ijo.2017.06.20

M3 - Article

VL - 10

SP - 961

EP - 967

JO - International Journal of Ophthalmology

JF - International Journal of Ophthalmology

SN - 2222-3959

IS - 6

ER -